Tariffs

(WASHINGTON, D.C.) — The Consumer Healthcare Products Association (CHPA) today responded to an announcement from the Department of Commerce this week regarding the initiation of a Section 232 investigation into the national security implications of pharmaceutical imports, including finished drug products, active pharmaceutical ingredients (APIs), and other critical materials:

(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the below statement following President Trump imposing a 25% tariff on imports from Mexico and Canada, which were originally set to take effect Tuesday, Feb. 4 at 12:01 a.m. EST. As of this morning, the Trump Administration has agreed to pause sweeping tariffs on Mexico for one month while the two sides work on an agreement.